Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy is a neuromuscular disorder for which immunological factors are undoubtedly important in the etiopathogenesis. As clinical recognition of this disorder has improved, immunosuppressive and immunomodulating treatments have emerged as the treatments of choice and the prognosis for patients with chronic inflammatory demyelinating polyneuropathy has improved. This review discusses the treatments most frequently employed and summarizes the evidence that establishes the beneficial impact these treatments have had on the clinical course of patients with chronic inflammatory demyelinating polyneuropathy.